Pharmacokinetic Evaluation of Newly Developed Oral Immediate Releaseand Sustained Release Dosage Forms of Losartan Potassium
暂无分享,去创建一个
[1] G. R. Pereira,et al. Multivariate optimization and validation of an analytical methodology by RP-HPLC for the determination of losartan potassium in capsules. , 2009, Talanta.
[2] L. Sasongko,et al. Simultaneous quantification of losartan and active metabolite in human plasma by liquid chromatography-tandem mass spectrometry using irbesartan as internal standard. , 2009, Journal of pharmaceutical and biomedical analysis.
[3] R. J. Tyrrell,et al. Development and validation of a stability-indicating HPLC method for the simultaneous determination of losartan potassium, hydrochlorothiazide, and their degradation products. , 2002, Journal of pharmaceutical and biomedical analysis.
[4] N. Erk. Analysis of binary mixtures of losartan potassium and hydrochlorothiazide by using high performance liquid chromatography, ratio derivative spectrophotometric and compensation technique. , 2001, Journal of pharmaceutical and biomedical analysis.
[5] Teven,et al. EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .
[6] Z. Zhao,et al. Identification of losartan degradates in stressed tablets by LC-MS and LC-MS/MS. , 1999, Journal of pharmaceutical and biomedical analysis.
[7] D. Sica,et al. Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[8] M. Lo,et al. An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection. , 1997, Journal of pharmaceutical and biomedical analysis.